Using an established preclinical tumor-bearing syngeneic mouse model, the combination of dazostinag and fractionated radiation displayed greater tumor regression compared with either treatment alone; however, the addition of an anti–PD-1 antibody did not further enhance the antitumor activity of dazostinag plus RT in this model. This evidence concerns the gene PDCD1 and neoplasm.